We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Reviewers Likely to Go Easy on GSK, Theravance’s Relovair: Analyst
FDA Reviewers Likely to Go Easy on GSK, Theravance’s Relovair: Analyst
March 30, 2012
The FDA will probably take a more lenient approach in reviewing the recent mixed trial results for GlaxoSmithKline (GSK) and Theravance’s chronic obstructive pulmonary disease (COPD) drug Relovair when the pair file later this year, an analyst says.